| Literature DB >> 24197666 |
Edward Ryder1, Brendan Doe, Diane Gleeson, Richard Houghton, Priya Dalvi, Evelyn Grau, Bishoy Habib, Evelina Miklejewska, Stuart Newman, Debarati Sethi, Caroline Sinclair, Sapna Vyas, Hannah Wardle-Jones, Joanna Bottomley, James Bussell, Antonella Galli, Jennifer Salisbury, Ramiro Ramirez-Solis.
Abstract
We describe here use of a cell-permeable Cre to efficiently convert the EUCOMM/KOMP-CSD tm1a allele to the tm1b form in preimplantation mouse embryos in a high-throughput manner, consistent with the requirements of the International Mouse Phenotyping Consortium-affiliated NIH KOMP2 project. This method results in rapid allele conversion and minimizes the use of experimental animals when compared to conventional Cre transgenic mouse breeding, resulting in a significant reduction in costs and time with increased welfare benefits.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24197666 PMCID: PMC3890051 DOI: 10.1007/s11248-013-9764-x
Source DB: PubMed Journal: Transgenic Res ISSN: 0962-8819 Impact factor: 2.788
Fig. 1EUCOMM/KOMP-CSD allele structure and consequences of Cre-mediated excision. Mutant alleles based on the promoter-driven cassette have three loxP sites and can therefore have multiple outcomes after exposure to Cre recombinase. The desired result is tm1b where the neo selection cassette and floxed exon are removed. The tm1b.1 form removes only the critical exon and the tm1b.2 form removes only the neo selection marker, neither of which fulfills the requirement of the KOMP2 project. Alleles based on the promoterless cassette have only two loxP sites which flank the critical exon. Binding sites for the universal short range PCR and real-time qPCR genotyping assays are also shown
A combination of six PCR-based assays can be used to detect the Cre driver, the mouse genotype and any conversion from the tm1a to the tm1b forms of the mutant allele
| Conversion | srPCR assay | qPCR assay | |||
|---|---|---|---|---|---|
| tm1b | Flox | tm1b_prom | LacZ count |
| |
|
| |||||
| No conversion (tm1a) | 2,337 bp + CE size | Dependent on CE size | Fail | No change | No change |
| tm1b.1—only critical exon (CE) removed | 2,291 bp | 128 bp | Fail | No change | No change |
| tm1b.2—only | 426 bp + CE size | Fail | Fail | No change | −1 copy |
| Full conversion to tm1b | 380 bp | Fail | Pass | No change | −1 copy |
|
| |||||
| No conversion (tm1a) | 1,580 bp + CE size | Dependent on CE size | Fail | No change | No change |
| tm1b | 1457 bp | 128 bp | Fail | No change | No change |
Using this method, the mice can be genotyped in a mutant strain-independent manner using the LacZ qPCR assay which counts the number of copies of the cassette present and is unaffected by tm1b conversion. If no qPCR technologies are available then the short range PCR (srPCR) can be used to detect conversion and the mice genotyped by other methods (e.g. gene specific PCR assays designed to discriminate between the mutant and WT alleles). The tests show some redundancy and are used to cross-verify and interpret the results
Fig. 2a Efficiency of conversion in HTN-Cre is much higher than if using CMV-Cre transgenic animals, with 27/64 strains showing 100 % conversion by genotyping. b The time taken to produce a mouse converted to tm1b with no Cre driver still present varies from 83 to over 200 days using CMV-Cre, whereas the treatment with HTN-Cre during IVF recovery takes less than 21 days
Summary of CMV-Cre transgenic breeding and cell permeable HTN-Cre
| Method | Genes | Mutants genotyped | Conversion to tm1b and cre removed | % conversion | Average # days from initial mating to first tm1b mouse with cre removed |
|---|---|---|---|---|---|
| HTN-Cre—via IVF | 64 | 423 | 333 | 79 | 20 |
| CMV-Cre—natural mating | 34 | 926 | 191 | 21 | 131 |
Conversion rate in HTN-Cre is nearly four times greater than using CMV-Cre transgenic breeding and the time needed for conversion is much faster
Fig. 3X-gal staining of a reporter line treated with cell permeable Cre results shows complete excision of the neo cassette, allowing ubiquitous expression of the lacZ gene
HTN-Cre treatment has no detrimental effect on the survival of the embryos during transfer to pseudo-pregnant females and subsequent births
| HTN-Cre treated | # Recipients | # non-pregnancies | # Embryos transferred | # Pups born | % Pups born |
|---|---|---|---|---|---|
| Yes | 177 | 27 (15 %) | 2,318 | 975 | 42 |
| No | 360 | 83 (23 %) | 4,976 | 1,800 | 36 |